Solvay lowers 2026 guidance as Middle East conflict weighs on third quarter

what happened

Reuters reports that Solvay lowered its 2026 guidance after the Middle East conflict and a halt at a peroxide unit in the Sadara complex in Saudi Arabia weighed on third-quarter results. The company now expects full-year EBITDA in a range of 720 to 740 million euros, slightly below the 775 million euro consensus it compiled itself. Free cash flow is now projected at 120 to 150 million euros. Earlier, Solvay had targeted underlying EBITDA of 770 to 850 million euros and free cash flow of at least 200 million euros.

Preliminary underlying EBITDA for the third quarter came in at 173 million euros, 7% below consensus, while sales of 1.03 billion euros matched expectations. According to the company, the conflict reduced quarterly EBITDA by about 25 million euros, of which nearly 15 million stemmed from the peroxide shutdown. Solvay is looking at ways to soften the financial hit, including joint-venture contract provisions that could allow it to recover lost profit.

why it matters

Solvay is a large European chemicals group, so a guidance cut tied to one plant outage and a regional conflict matters for the sector and for investors tracking costs and revenue across chemicals. The key question is whether the joint-venture compensation clause will work as the company hopes.

market impact

European chemicals: Solvay's lower outlook signals pressure on the company's earnings expectations

tags

instruments